Jubilant Pharmova Limited — Investor Meet, 07-08-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Jubilant Pharmova reported strong Q1FY26 results with total revenue up 10% YoY to Rs. 1,901 Cr. and EBITDA up 14% to Rs. 302 Cr., with improved margins. Key growth drivers include Ruby-Fill in Radiopharma and ongoing capacity expansion in CDMO Sterile Injectables, with Line 3 progressing ahead of expectations. CRDMO is scaling up large pharma contracts and expanding capacity. Proprietary Novel Drugs’ lead programs are advancing in clinical trials. The company's Vision 2030 targets 2x revenue, 23-25% EBITDA margins, zero net debt, and high teens RoCE, indicating a confident outlook.